Sentence examples for min before morphine from inspiring English sources

pretreatment 30 min before morphine injection.

The icv administration of the highly selective σ1R antagonist S1RA [E-52862; (53)] at 10 or 30 min before morphine treatment (3 nmol, icv) increased the analgesic activity when evaluated at 30 min postopioid injection.

One-way ANOVA showed that acute baclofen pretreatment 15 min before morphine challenge dose-dependently inhibited the expression of morphine-induced behavioral sensitization [F 4,35) = 6.32, P < 0.01].

The presence of 3 nmol S1RA, administered 30 min before morphine treatment, nearly abolished CaMKII activation, reduced NR1/NR2 phosphorylation, and preserved the MOR-NR1 inhibitory association during the intervals that corresponded to the morphine analgesic time-course and beyond (Fig. 5C and Supplementary Fig. S4).

The administration of S1RA at 10 min or 30 min before morphine administration reduced the opioid-induced phosphorylation of the NR1/NR2 subunits and promoted an early re-association of NR1 subunits under MOR-HINT1-negative control, thereby limiting the activity of the NMDAR-CaMKII pathway (Figs. 5C, 6A and 10A).

The analgesic response diminished during the chronic morphine protocol; however, on day 7, the icv administration of 3 nmol S1RA 20 min before morphine enabled the opioid to produce an analgesic effect comparable to that of the first 10 nmol dose delivered on day 0 of the assay.

Controls were injected only with the opioid priming dose, whereas the experimental groups received the drug under study before the morphine priming dose or 24 h later for a few minutes (typically 30 min) before the morphine test dose of 10 nmol morphine.

injection of pifithrin-α (1 and 10 nmol), an inhibitor of p53 activation, benzyloxycarbonyl-Val-Ala-Asp(OMe -fluoromethylketone (Z-VAD-fmk) (1 and 10 nmOMe -fluoromethylketonespase inhibitor, or NG-nitro-l-arginine methyl ester (l-NAME) (2 and 20 nmol), a non-selective inhibitor of nitric oxide synthase, 5 min before each morphine treatment during the induction, with none given on the test day.

The AJN pre-treatment group was administered AJN 30 min before each morphine administration, and the AJN post-treatment groups were treated with AJN for 10 days after withdrawal.

AJN was dissolved in deionized water and intragastrically administered to the rats in the AJN pre-treatment group at a dose of 0.555 g/kg (1 mL/kg of body weight) 30 min before each morphine injection.

roscovitine administered 30 min before each morphine injection dose-dependently decreased the antinociceptive effect of Dlt II as compared with vehicle-treated rats and this effect reached statistical significance with 30 μg roscovitine (14.8 ± 8.7 % MPE compared with 47.9 ± 5.4 % MPE for 30 μg and vehicle respectively, P < 0.05 using one-way anova with Tukey's multiple comparisons test).